Six surprisingly hopeful advances in the battle against dementia

In autumn 2019, the mood within the field of dementia research was bleak. Multiple late-stage clinical trials had ended in ...

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the …

Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), ...

Breakthrough dementia drugs — what went wrong and what happens next?

Two Alzheimer's drugs were hailed as treatments that would transform care. Why are barely any UK patients getting them?
Morningstar

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International ...
Nasdaq

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

TOKYO, Mar 11, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S.
Nasdaq

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

TOKYO and CAMBRIDGE, Mass., Mar 23, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today that new real-world findings from an analysis of long-term treatment persistence and ...

Alzheimer’s drug co-developed by Eisai approved for use in Japan

The health ministry approved a medication that helps slow progression of Alzheimer’s disease in the early stages, meaning the ...
Morningstar

FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...